TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01614197
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
Study: NCT01614197
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Study: NCT01614197
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Study: NCT02532400
Drug: Neoadjuvant endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
Study: NCT00258063
Drug: EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01739335
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo Oral Tablets once daily for 7 days
Study: NCT00499122
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00499122
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02074553
Drug: Ro542-4802/F03 (Reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
Study: NCT02074553
Drug: Ro542-4802/F07 (Test)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
Study: NCT02074553
Drug: Ro542-4802/F08 (Test)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
Study: NCT02074553
Drug: Ro542-4802/F14 (Test)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
Study: NCT01600521
Drug: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
Study: NCT02888704
Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of the drug in the aspect of safety and efficacy.
Study: NCT00118755
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
Study: NCT00118755
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
Study: NCT03005860
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
Study: NCT03681704
Drug: HuangQi Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuangQi Decoction 150ml twice a day for 24 weeks
Study: NCT03681704
Drug: HuangQi Decoction placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
Study: NCT02118558
Drug: standard prophylactic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
Study: NCT00546403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with placebo
Study: NCT01248416
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01771328
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
Study: NCT03098420
Drug: Normal saline 0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Study: NCT02521311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Study: NCT02095951
Drug: Ethanol lock therapy (ELT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
Study: NCT03618823
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT03618823
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT00054054
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01131234
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01115751
Drug: LY2780301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression.
Study: NCT01785641
Drug: cefazolin+gentamicin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
Study: NCT01674725
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT01015183
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
Study: NCT01015183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: as the same of intervention group
Study: NCT04170023
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FD inhibitor
Study: NCT03374111
Drug: Colla corii asini
Normalized name: CORID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g Colla corii asini granule daily for 8 weeks
Study: NCT01079455
Drug: Corticosterone
Normalized name: Corticosterone
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
Study: NCT01153854
Drug: Placebo groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
Study: NCT02709746
Drug: Fluoxetine 20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Study: NCT01403662
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
Study: NCT00176046
Drug: viscum album pini
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection of 0,001-20 mg 3 times per week
Study: NCT00176046
Drug: viscum album pini
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection 0,001-20 mg 3 times per week
Study: NCT03074695
Drug: Standard Epidural (EPL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
Study: NCT01207297
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
Study: NCT01312012
Drug: antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
Study: NCT04196101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets daily for 5 days
Study: NCT00903630
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
Study: NCT00284986
Drug: Prochymal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
Study: NCT00913120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02930785
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)
Study: NCT02271113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02524119
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
Study: NCT00293631
Drug: Lornoxicam 8 mg
Normalized name: lornoxicam 8 MG
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293631
Drug: Lornoxicam 16 mg
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293631
Drug: Ketorolac 30 mg
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00293631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03377426
Drug: LYS228
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS228 IV infusion
Study: NCT03377426
Drug: Standard of care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of standard of care antibiotics
Study: NCT04549194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
Study: NCT01586000
Drug: 20 µg/day E2 with NES 200® µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
Study: NCT01498653
Drug: GW685698/GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA
Study: NCT01498653
Drug: CCI18781
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS
Study: NCT00684502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
Study: NCT01052662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally everyday for 12 weeks
Study: NCT06084156
Drug: HSK7653
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
Study: NCT01442818
Drug: Dilaudid IV Scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse administered IV Dilaudid 0.5mg every 2 hours.
Study: NCT02628847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01208441
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03005964
Drug: AM001 Cream, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Cream
Study: NCT03005964
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01880515
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
Study: NCT01477333
Drug: UT-15C SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiated at 0.125 mg BID, titrated as clinically indicated.
Study: NCT01477333
Drug: Tyvaso Inhalation Solution
Normalized name: Tyvaso Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
Study: NCT01765465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524315
Drug: Vitamin B1-ratiopharm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
Study: NCT01524315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml normal saline, intravenous, preoperative
Study: NCT00669799
Drug: gentamyacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal
Study: NCT02121834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719861
Drug: Desipramine HCL
Normalized name: desipramine HCl
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
Study: NCT04479631
Drug: BRII-196
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-196 given intravenously
Study: NCT04479631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given intravenously
Study: NCT04236115
Drug: Prilocain 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prilocaine is dental local anaesthetic agent
Study: NCT02690922
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3g/m2 1day
Study: NCT00617474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00491829
Drug: 50 mg qhs
Approvals — FDA: no, EMA: no, PMDA: no
Description: flibanserin 50 mg
Study: NCT00491829
Drug: 100 mg
Normalized name: urea 100 MG
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flibanserin 100mg
Study: NCT00491829
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01047293
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells.
Study: NCT01047293
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
Study: NCT02375178
Drug: Sterile saline solution
Normalized name: Blairex Sterile Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
Study: NCT00369811
Drug: Oxycodone, fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01580969
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
Study: NCT04354896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Study: NCT00070629
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6
Study: NCT03433248
Drug: EMPA/LINA 10/5 mg QD (n=22)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
Study: NCT03433248
Drug: LINA/EMPA 5/10 mg QD (N=22)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
Study: NCT04302441
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
Study: NCT00138528
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01048580
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
Study: NCT00942240
Drug: ACU-4429
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once a day for 14 days
Study: NCT00942240
Drug: matching placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once a day for 14 days
Study: NCT02490202
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Study: NCT00004252
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004252
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes